Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia
| Course Id | 251005 |
| Course Name | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia |
| Course Catagory | Respiratory Care, Nursing and General Healthcare |
| Course Price | 33.54 |
| Course CEU | 3 |
Course Objectives
Upon successful completion of this module, you will be able to:
- Differentiate among hospital-acquired pneumonia, ventilator-associated pneumonia, and the retired classification of healthcare-associated pneumonia, and explain the evidence-based rationale for the elimination of the HCAP category from current guidelines.
- Describe the epidemiologic burden of HAP and VAP, including incidence trends, attributable mortality, and the impact of surveillance definition changes such as the ventilator-associated event (VAE) framework.
- Explain the pathophysiologic mechanisms by which oropharyngeal colonization, micro-aspiration, biofilm formation, and impaired host defenses converge to produce nosocomial pneumonia in intubated and non-intubated patients.
- Identify patient-specific, device-related, and healthcare-setting risk factors that predispose hospitalized adults to HAP and VAP, including modifiable and non-modifiable contributors.
- Analyze the current evidence regarding diagnostic strategies for suspected HAP/VAP, including the comparative roles of clinical criteria, radiographic imaging, noninvasive versus invasive respiratory sampling, quantitative and semiquantitative culture thresholds, and emerging biomarkers.
- Apply a risk-stratified framework for selecting empiric antimicrobial therapy based on risk factors for multidrug-resistant (MDR) organisms, local antibiograms, and severity of illness.
- Formulate an evidence-based plan for antimicrobial de-escalation, duration of therapy, and use of procalcitonin or clinical criteria to guide discontinuation of antibiotics.
- Evaluate the management of HAP/VAP caused by specific MDR pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, and Acinetobacter baumannii.
- Describe evidence-based, multicomponent prevention strategies for VAP and non-ventilator hospital-acquired pneumonia (NV-HAP), including ventilator liberation bundles, oral care protocols, and surveillance methodologies.
- Integrate principles of antimicrobial stewardship, quality improvement, and interprofessional collaboration into the comprehensive management of patients with nosocomial pneumonia.